Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YAP1 | P46937 | 3/20 | 0.65 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.61 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.57 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.54 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | STS | P08842 | 1/20 | 0.53 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7326386 | 0.91 | GPR119 (0.61) | YAP1GPR119TEAD1TEAD3KDM4E | |
| SCHEMBL2158159 | 0.91 | GPR119 (0.65) | YAP1GPR119TEAD1TEAD3KDM4E | |
| SCHEMBL12813454 | 0.90 | YAP1 (0.66) | YAP1GPR119PRMT5KDM4EPKM | |
| SCHEMBL944418 | 0.90 | GPR119 (0.57) | YAP1GPR119PRMT5TEAD1TEAD3 | |
| SCHEMBL22366347 | 0.87 | YAP1 (0.56) | YAP1GPR119PRMT5KDM4EPKM | |
| SCHEMBL3251863 | 0.86 | KDM4E (0.58) | YAP1GPR119KDM4EPKMSTS | |
| SCHEMBL3356937 | 0.86 | TEAD1 (0.60) | TEAD1TEAD3KDM4E | |
| SCHEMBL22193619 | 0.85 | PRMT5 (0.61) | YAP1GPR119PRMT5KDM4EPKM | |
| SCHEMBL76105 | 0.85 | YAP1 (0.60) | YAP1GPR119PRMT5STS | |
| SCHEMBL16385072 | 0.85 | GPR119 (0.67) | GPR119TEAD1TEAD3KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130184313-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184313-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-07-18 | — | — | US | disclosed |
| US-8445684-B2 | Nicotinic acetylcholine receptor ligands and the uses thereof | PsycoGenics Inc. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445684-B2 | Nicotinic acetylcholine receptor ligands and the uses thereof | PsycoGenics Inc. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20100152450-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | PSYCHOGENICS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20100152450-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | PSYCHOGENICS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| EP-0674514-A1 | USE OF ARYLOXYALKYL SUBSTITUTED CYCLIC AMINES AS CALCIUM CHANNEL ANTAGONISTS AND NEW PHENYLOXYALKYL PIPERIDIN DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1995-10-04 | — | — | EP | disclosed |
| WO-1994013291-A1 | USE OF ARYLOXYALKYL SUBSTITUTED CYCLIC AMINES AS CALCIUM CHANNEL ANTAGONISTS AND NEW PHENYLOXYALKYL PIPERIDIN DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152450-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | CHRNG, CHRNA5, CHRNA2 | YAP1 4383/4885GPR119 223/4885PRMT5 1026/4885 |
| US-20130184313-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS AND THE USES THEREOF | CHRNG, CHRNA5, CHRNA2 | YAP1 4383/4885GPR119 223/4885PRMT5 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.